 | Up a level |
Cano, Antonio; Nappi, Rossella E; Santoro, Nanette; Stute, Petra; Blogg, Martin; English, Marci L; Morga, Antonia; Scrine, Ludmila; Siddiqui, Emad; Ottery, Faith D (2024). Fezolinetant impact on health-related quality of life for vasomotor symptoms due to the menopause: Pooled data from SKYLIGHT 1 and SKYLIGHT 2 randomised controlled trials. BJOG : an international journal of obstetrics and gynaecology, 131(9), pp. 1296-1305. Wiley 10.1111/1471-0528.17773
Nappi, Rossella E; Johnson, Kimball A; Stute, Petra; Blogg, Martin; English, Marci; Morga, Antonia; Scrine, Ludmila; Siddiqui, Emad; Ottery, Faith D (2024). Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2). Menopause, 31(6), pp. 512-521. The North American menopause Society 10.1097/GME.0000000000002354
Stute, Petra; Cano, Antonio; Thurston, Rebecca C; Small, Mark; Lee, Lauren; Scott, Megan; Siddiqui, Emad; Schultz, Neil M (2023). Corrigendum to "Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States" [Maturitas 164 (October 2022) 38-45]. Maturitas, 169, p. 55. Elsevier 10.1016/j.maturitas.2022.11.003
Stute, Petra; Cano, Antonio; Thurston, Rebecca C; Small, Mark; Lee, Lauren; Scott, Megan; Siddiqui, Emad; Schultz, Neil M (2022). Evaluation of the impact, treatment patterns, and patient and physician perceptions of vasomotor symptoms associated with menopause in Europe and the United States. Maturitas, 164, pp. 38-45. Elsevier 10.1016/j.maturitas.2022.06.008
